Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit
Ma, Y. T.
Hubner, Richard A
Palmer, D. H.
Luong, T. V.
AffiliationDepartment of Oncology, Royal Free London NHS Foundation Trust, London, UK
MetadataShow full item record
AbstractBackground: Advanced hepatocellular carcinoma (HCC) is commonly diagnosed using non-invasive radiological criteria (NIRC) defined by the European Association for the Study of the Liver or the American Association for the Study of Liver Diseases. In 2017, The National Institute for Clinical Excellence mandated histological confirmation of disease to authorise the use of sorafenib in the UK. Methods: This was a prospective multicentre audit in which patients suitable for sorafenib were identified at multidisciplinary meetings. The primary analysis cohort (PAC) was defined by the presence of Child-Pugh class A liver disease and performance status 0-2. Clinical, radiological and histological data were reported locally and collected on a standardised case report form. Results: Eleven centres reported 418 cases, of which 361 comprised the PAC. Overall, 76% had chronic liver disease and 66% were cirrhotic. The diagnostic imaging was computed tomography in 71%, magnetic resonance imaging in 27% and 2% had both. Pre-existing histology was available in 45 patients and 270 underwent a new biopsy, which confirmed HCC in 93.4%. Alternative histological diagnoses included cholangiocarcinoma (CC) and combined HCC-CC. In cirrhotic patients, NIRC criteria had a sensitivity of 65.4% and a positive predictive value of 91.4% to detect HCC. Two patients (0.7%) experienced mild post-biopsy bleeding. Conclusion: The diagnostic biopsy is safe and feasible for most patients eligible for systemic therapy.
CitationChilds A, Zakeri N, Ma YT, O’Rourke J, Ross P, Hashem E, et al. Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit. Br J Cancer. 2021 Sep 15.
JournalBritish Journal of Cancer
- Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
- Authors: Terzi E, Iavarone M, Pompili M, Veronese L, Cabibbo G, Fraquelli M, Riccardi L, De Bonis L, Sangiovanni A, Leoni S, Zocco MA, Rossi S, Alessi N, Wilson SR, Piscaglia F, CEUS LI-RADS Italy study group collaborators:
- Issue date: 2018 Mar
- Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance.
- Authors: Iavarone M, Viganò M, Piazza N, Occhipinti V, Sangiovanni A, Maggioni M, D'Ambrosio G, Forzenigo LV, Motta F, Lampertico P, Rumi MG, Colombo M
- Issue date: 2019 Mar-Apr
- Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules ≤2 cm in cirrhosis.
- Authors: Ayuso C, Forner A, Darnell A, Rimola J, García-Criado Á, Bianchi L, Vilana R, Oliveira R, Llarch N, Bruix J
- Issue date: 2019 Jul
- Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular-cholangiocarcinoma.
- Authors: Gigante E, Ronot M, Bertin C, Ciolina M, Bouattour M, Dondero F, Cauchy F, Soubrane O, Vilgrain V, Paradis V
- Issue date: 2019 Dec
- Liver transplantation in cirrhotic patients with small hepatocellular carcinoma: an analysis of pre-operative imaging, explant histology and prognostic histologic indicators.
- Authors: Bhattacharjya S, Bhattacharjya T, Quaglia A, Dhillon AP, Burroughs AK, Patch DW, Tibballs JM, Watkinson AF, Rolles K, Davidson BR
- Issue date: 2004